Ligand Pharmaceuticals Incorporated (LGND)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-27) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-27) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-08) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Comprehensive (loss) Income | — |
|
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Statement of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statement of Stockholders' Equity (P) | — |
|
| Notes | ||
| Acquisitions | ||
| Agenus Transaction | ||
| Apeiron Acquisition | — |
|
| Assets Held For Sale | — |
|
| Balance Sheet Account Details | — |
|
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Castle Creek and Agenus Transactions | — |
|
| Commercial License and Other Economic Rights | — |
|
| Commitment and Contingencies | — |
|
| Commitment and Contingencies: Legal Proceedings | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | ||
| Fair Value Measurements | ||
| Financial Royalty Assets, Net | ||
| Financial Royalty Assets, Net (formerly Known As Commercial License Rights) | ||
| Income Tax | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Investment Transactions | ||
| Leases | — |
|
| Pay Vs Performance Disclosure | ||
| Pelthos Transaction | ||
| Sale of Pelican Business and Investment In Primrose Bio | ||
| Spin-off of Omniab | ||
| Stockholders' Equity | ||
| Subsequent Event | ||